Clinical Trials
73 trialsNCT03449108 2026-05-22
LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04759911 2026-05-20
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07470489 2026-04-16
Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Not yet recruiting
NCT07485569 2026-04-15
REPOTHYROID-II
Radboud University Medical Center
Phase 1 Not yet recruiting
NCT05696548 2026-04-09
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
National Cancer Center Hospital East
Phase 2 Active not recruiting
NCT03975231 2026-04-08
Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT07440290 2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3 Not yet recruiting
NCT07068542 2026-02-24
TROPION
Zhejiang Provincial People's Hospital
Phase NA Recruiting
NCT04675710 2026-02-19
Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04171622 2026-02-17
Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06639191 2026-01-30
AKIR001
Karolinska University Hospital
Phase EARLY_PHASE1 Recruiting
NCT03181100 2026-01-09
Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05768178 2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3 Recruiting
NCT06902376 2025-11-05
NEO-COMBATXL
UNC Lineberger Comprehensive Cancer Center
Phase 1 Recruiting
NCT05453799 2025-10-20
Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
Northwestern University
Phase 2 Active not recruiting
NCT06790706 2025-10-06
IMMUNORARE5
Hospices Civils de Lyon
Phase 2 Recruiting
NCT07181720 2025-10-02
CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Chongqing Precision Biotech Co., Ltd
Phase 1 Recruiting
NCT06374602 2025-09-05
Efficacy of Pembrolizumab and Lenvatinib in Patients With Anaplastic Thyroid Cancer
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT04418167 2025-09-03
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
Phase 1 Suspended
NCT03085056 2025-07-03
Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04238624 2025-07-02
Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT04400474 2025-06-19
CABATEN
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT04579757 2025-05-08
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Hutchmed
Phase 1/2 Terminated
NCT04420754 2025-03-30
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
AffyImmune Therapeutics, Inc.
Phase 1 Active not recruiting
NCT02152137 2025-01-27
Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT06235216 2024-11-01
SETHY
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Recruiting
NCT03565536 2024-04-19
Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Fujian Medical University
Phase 2 Completed
NCT06362694 2024-04-12
Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy
Saint Petersburg State University, Russia
Phase 2 Recruiting
NCT04739566 2024-03-25
ANAPLAST-NEO
Saint Petersburg State University, Russia
Phase 2 Withdrawn
NCT02244463 2024-01-12
A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT06079333 2023-10-12
NEO-ATACT
Leiden University Medical Center
Phase 2 Recruiting
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT05102292 2023-08-21
The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
Shanghai Henlius Biotech
Phase 1/2 Unknown
NCT02404441 2022-08-03
Phase I/II Study of PDR001 in Patients With Advanced Malignancies
Novartis
Phase 1/2 Completed
NCT01236547 2022-07-19
Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT03122496 2022-06-08
Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02688608 2022-02-10
Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT02012231 2020-10-19
Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers.
Fore Biotherapeutics
Phase 1 Terminated
NCT04574817 2020-10-05
Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
Taizhou Hanzhong biomedical co. LTD
Phase 2 Unknown
NCT00603941 2020-09-16
A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
Daiichi Sankyo
Phase 1/2 Terminated
NCT02726503 2020-06-17
HOPE
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Phase 2 Completed
NCT03211117 2020-03-25
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
Mayo Clinic
Phase 2 Completed
NCT00625846 2020-02-26
Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00654238 2019-11-18
Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
University of Pennsylvania
Phase 2 Completed
NCT02657369 2019-10-15
A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
Eisai Inc.
Phase 2 Terminated
NCT02289144 2019-07-30
Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
University of Texas Southwestern Medical Center
Phase 2 Withdrawn
NCT03002623 2018-12-21
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00804830 2018-08-28
Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
Region Skane
Phase 2 Terminated
NCT00416949 2018-07-18
Iodine I 131 in Treating Patients With Thyroid Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase NA Terminated